Barclays PLC Acquires 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Barclays PLC raised its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 210.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,110 shares of the company's stock after acquiring an additional 30,585 shares during the quarter. Barclays PLC owned approximately 0.12% of Entrada Therapeutics worth $720,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC increased its holdings in Entrada Therapeutics by 10.5% during the 3rd quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company's stock valued at $27,358,000 after purchasing an additional 161,962 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Entrada Therapeutics by 132.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company's stock worth $2,215,000 after purchasing an additional 78,953 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Entrada Therapeutics in the third quarter valued at $1,109,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Entrada Therapeutics by 50.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company's stock valued at $3,225,000 after buying an additional 67,559 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Entrada Therapeutics by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock worth $9,214,000 after acquiring an additional 46,512 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company's stock.

Analyst Ratings Changes

TRDA has been the subject of a number of research analyst reports. Oppenheimer boosted their target price on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 6th. Roth Mkm started coverage on Entrada Therapeutics in a report on Thursday, December 5th. They set a "buy" rating and a $29.00 price objective on the stock. HC Wainwright increased their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Finally, Roth Capital upgraded Entrada Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th.

Insider Buying and Selling at Entrada Therapeutics

In related news, insider Natarajan Sethuraman sold 1,409 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $20.01, for a total value of $28,194.09. Following the completion of the sale, the insider now owns 163,588 shares in the company, valued at approximately $3,273,395.88. This represents a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Kory James Wentworth sold 8,637 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the transaction, the chief financial officer now owns 73,849 shares in the company, valued at approximately $1,475,503.02. This trade represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,681 shares of company stock worth $851,199. Insiders own 7.59% of the company's stock.

Entrada Therapeutics Stock Up 2.4 %

NASDAQ TRDA traded up $0.29 during trading hours on Thursday, hitting $12.54. The company's stock had a trading volume of 163,124 shares, compared to its average volume of 135,422. Entrada Therapeutics, Inc. has a twelve month low of $11.35 and a twelve month high of $21.79. The firm has a market capitalization of $469.25 million, a P/E ratio of 7.89 and a beta of -0.12. The stock has a fifty day moving average of $18.16 and a 200 day moving average of $16.86.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.